AI Insight
New research from the NIH shows that semaglutide, the active ingredient in Ozempic and Wegovy, triggers varied responses in appetite-regulating brain cells, explaining why these GLP-1 drugs produce different weight-loss outcomes across individuals. The study identified mechanisms behind the weight-loss plateau that many patients experience after initial success with these medications. Researchers also discovered potential strategies to extend the drugs' effectiveness and help patients overcome these plateaus.
Why it matters
This finding could lead to improved treatment strategies for obesity by helping clinicians predict patient responses and potentially develop combination therapies or modified dosing regimens to sustain weight loss beyond current limitations. Understanding individual variation in drug response may enable more personalized approaches to weight management.
New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus.
Source: Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
Explore the science behind this topic from a different angle: